Loading...
XNAS
AVGR
Market cap1mUSD
Feb 14, Last price  
0.47USD
Name

Avinger Inc

Chart & Performance

D1W1MN
P/E
P/S
0.20
EPS
Div Yield, %
Shrs. gr., 5y
194.27%
Rev. gr., 5y
-0.67%
Revenues
8m
-7.51%
8,560,00012,964,00011,213,00010,713,00019,214,0009,934,0007,915,0009,131,0008,761,00010,130,0008,273,0007,652,000
Net income
-18m
L+5.12%
-33,864,000-39,901,000-31,964,000-47,344,000-56,128,000-48,732,000-27,558,000-19,752,000-19,823,000-20,710,000-17,427,000-18,320,000
CFO
-14m
L-13.89%
-35,234,000-40,655,000-21,801,000-40,883,000-53,069,000-34,476,000-18,466,000-17,264,000-14,835,000-15,697,000-16,760,000-14,432,000
Earnings
Aug 06, 2025

Profile

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
IPO date
Jan 30, 2015
Employees
71
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,652
-7.51%
8,273
-18.33%
Cost of revenue
10,189
10,009
Unusual Expense (Income)
NOPBT
(2,537)
(1,736)
NOPBT Margin
Operating Taxes
(196)
Tax Rate
NOPAT
(2,537)
(1,540)
Net income
(18,320)
5.12%
(17,427)
-15.85%
Dividends
(4,510)
Dividend yield
Proceeds from repurchase of equity
5,112
5,196
BB yield
Debt
Debt current
15,395
15,257
Long-term debt
1,102
3,296
Deferred revenue
Other long-term liabilities
672
1,001
Net debt
11,222
3,950
Cash flow
Cash from operating activities
(14,432)
(16,760)
CAPEX
(8)
(51)
Cash from investing activities
(8)
(51)
Cash from financing activities
5,112
11,917
FCF
(561)
(2,285)
Balance
Cash
5,275
14,603
Long term investments
Excess cash
4,892
14,189
Stockholders' equity
(420,695)
(402,368)
Invested Capital
430,560
423,834
ROIC
ROCE
EV
Common stock shares outstanding
786
417
Price
Market cap
EV
EBITDA
(1,148)
(1,540)
EV/EBITDA
Interest
1,719
1,665
Interest/NOPBT